Ophthalmology

We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting- edge research. Vision loss affects 253 million people worldwide, presenting a major global health problem and diseases of the retina are among the main causes of visual impairment globally.

We have the broadest late stage retina pipeline including treatments for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR) and retinal vein occlusion (RVO). Our robust early stage pipeline also includes novel therapeutic modalities such as gene therapies, cell-based therapies and potential treatments for geographic atrophy (GA).

Our experienced team of ophthalmologists, scientists and researchers are working to develop innovative solutions that have the potential to preserve and restore vision.

Partnering opportunities we are looking for:

Retinal diseases and long-acting ocular drug delivery solutions
Glaucoma and dry eye disease

Example partnerships

AntlerA

Acquisition of Wnt targeting programs for potential best-in-class treatment for multiple indications including neovascular age-related macular degeneration and diabetic macular edema

Lineage Cell Therapeutics

Collaboration and license agreement for the development and commercialization of a retinal pigment epithelium (RPE) cell therapy for the treatment of ocular disorders, including advanced dry age-related macular degeneration (dry AMD) with geographic atrophy (GA).

Character Biosciences

Research collaboration and license agreement to better understand the genomic factors that increase an individual's risk for developing ocular diseases.

Pieris Pharmaceuticals

Research collaboration and license agreement to discover, develop and commercialize locally delivered ophthalmology therapies.

ForSight VISION4

Acquisition to acquire Susvimo™ for long-acting ocular delivery

SemaThera

Research collaboration targeting SEMA3A for diabetic retinopathy (DR)

Explore collaboration opportunities

Connect with our partnering experts to start the conversation.

Reach out

More Pharma partnering areas

View all areas

Digital and dataInnovation

We are taking PHC toward a future where treatments are targeted to an individual’s needs and unique genetic profile.

ImmunologyInnovation

Leading the way to advance science in inflammatory and autoimmune diseases.

Infectious DiseasesInnovation

We are advancing innovation to combat infectious diseases like HBV, influenza and MDR.

NeurologyInnovation

We focus on advances for neurodegenerative, psychiatric and neurodevelopmental disorders.

Oncology and HaematologyInnovation

We focus on first- and best-in-class therapeutics in molecular targeted therapies and cancer immunotherapy.

Research TechnologiesInnovation

We focus on therapeutic modalities and enabling technologies.

Cardiovascular, Renal & Metabolic DiseaseInnovation

Roche is committed to making a contribution to areas of huge unmet need and societal burden through transformative science like in cardiovascular and metabolic diseases

References

Word Health Organization. Blindness and vision impairment. [Internet; cited April 2022]. Available from: https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment